MedTrace Logo

SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes

NCT03982381 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2067

Last updated 2026-03-04

No results posted yet for this study

Summary

A real-world, nationwide, register-based, randomised trial (RRCT) comparing SGLT2 inhibitors with metformin as standard treatment in early typ 2 diabetes. An open-label trial addressing efficacy with respect to clinically important macro- and microvascular events.

Conditions

Interventions

DRUG

Metformin

Active comparator

DRUG

Dapagliflozin 10 MG

Experimental treatment

Sponsors & Collaborators

  • Uppsala University Hospital

    collaborator OTHER

  • Swedish Healthcare Regions

    collaborator UNKNOWN

  • National Board of Health and Welfare, Sweden

    collaborator OTHER_GOV

  • The Swedish National Diabetes Register

    collaborator UNKNOWN

  • Uppsala University

    lead OTHER

Principal Investigators

  • Jan Eriksson, MD · Uppsala University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-05
Primary Completion
2026-01-31
Completion
2026-01-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03982381 on ClinicalTrials.gov